Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) Other Non Operating Income (2016 - 2025)

Protalix BioTherapeutics has reported Other Non Operating Income over the past 16 years, most recently at -$701000.0 for Q4 2025.

  • Quarterly results put Other Non Operating Income at -$701000.0 for Q4 2025, down 720.35% from a year ago — trailing twelve months through Dec 2025 was $278000.0 (down 78.6% YoY), and the annual figure for FY2025 was $117000.0, down 90.99%.
  • Other Non Operating Income for Q4 2025 was -$701000.0 at Protalix BioTherapeutics, down from $288000.0 in the prior quarter.
  • Over the last five years, Other Non Operating Income for PLX hit a ceiling of $813000.0 in Q2 2022 and a floor of -$701000.0 in Q4 2025.
  • Median Other Non Operating Income over the past 5 years was $199500.0 (2022), compared with a mean of $228750.0.
  • Peak annual rise in Other Non Operating Income hit 535.16% in 2022, while the deepest fall reached 3150.0% in 2022.
  • Protalix BioTherapeutics' Other Non Operating Income stood at -$2000.0 in 2021, then tumbled by 3150.0% to -$65000.0 in 2022, then skyrocketed by 43.08% to -$37000.0 in 2023, then soared by 405.41% to $113000.0 in 2024, then tumbled by 720.35% to -$701000.0 in 2025.
  • The last three reported values for Other Non Operating Income were -$701000.0 (Q4 2025), $288000.0 (Q3 2025), and $272000.0 (Q2 2025) per Business Quant data.